1. Introduction {#sec1-cancers-12-02262}
===============

Hepatocellular carcinoma (HCC), represents about 90% of primary liver tumors \[[@B1-cancers-12-02262]\] and is the fifth most common malignancy worldwide \[[@B2-cancers-12-02262]\]. Surgical resection is an efficient therapy that prolongs patient survival, but the five-year recurrence rate is still relatively high, at 70% \[[@B3-cancers-12-02262],[@B4-cancers-12-02262],[@B5-cancers-12-02262]\]. Palliative treatment of advanced liver cancer with the oral multikinase inhibitor sorafenib leads to an overall survival (OS) of approximately 10.7 months (95% CI, 9.4 to 13.3) \[[@B6-cancers-12-02262]\]. HCC's dismal prognosis is partly due to the tumor's high intrinsic and/or acquired resistance to most of the drugs used in first- and second-line therapy.

The expression of heat shock proteins (HSPs) is rapidly activated when cells undergo physical and chemical damage like hypoxia \[[@B7-cancers-12-02262],[@B8-cancers-12-02262]\]. Within the HSPs family, HSP70 is the easiest to induce and increases dramatically under stress \[[@B9-cancers-12-02262],[@B10-cancers-12-02262]\]. HSPA1A and HSPA1B, the principal members of the HSP70 family produced in response to stress, are collectively referred to as HSP70 \[[@B11-cancers-12-02262],[@B12-cancers-12-02262]\]. HSP70 is well known for functioning as a molecular chaperone by assisting in the folding and assembly of newly-synthesized proteins and participating in membrane translocation and protein transportation \[[@B13-cancers-12-02262],[@B14-cancers-12-02262],[@B15-cancers-12-02262],[@B16-cancers-12-02262]\]. In addition, HSP70 plays a critical role in many unique features of malignant tumors, including uncontrolled proliferation, malignant transformation, and metastasis \[[@B17-cancers-12-02262],[@B18-cancers-12-02262],[@B19-cancers-12-02262],[@B20-cancers-12-02262]\]. During the process of tumor formation, a large amount of HSP70 is required to regulate and stabilize the abnormal proliferation process of tumor cells' continuous proliferation and anabolic enhancement \[[@B21-cancers-12-02262]\]. Previous studies have also shown that HSP70 is involved in cell protection and survival in response to hypoxia \[[@B22-cancers-12-02262],[@B23-cancers-12-02262]\]. HSP70 is one of the internationally recognized and recommended immunostaining indicators for the identification of high-grade malignant dysplastic nodules and early HCC \[[@B24-cancers-12-02262],[@B25-cancers-12-02262]\]. A study indicated that raised levels of HSP70 were previously related to vascular infiltration and poor disease-free survival (DFS) \[[@B26-cancers-12-02262]\]. However, whether HSP70 is a prognostic factor for HCC is discussed controversially \[[@B27-cancers-12-02262]\].

The regulation of the initial stage of protein synthesis is crucial for cell proliferation, apoptosis, and carcinogenesis \[[@B28-cancers-12-02262],[@B29-cancers-12-02262]\]. This process is initiated by the eIF4F complex, which is composed of eIF4A, eIF4E, and eIF4G \[[@B30-cancers-12-02262],[@B31-cancers-12-02262],[@B32-cancers-12-02262]\]. eIF4E and eIF4G interaction is considered a crucial step in mRNA translation initiation \[[@B33-cancers-12-02262],[@B34-cancers-12-02262]\]. 4EBP1 inhibits the formation of eIF4F complex by competitively occupying the eIF4E binding site with eIF4G and interfering in the eIF4E--eIF4G interaction \[[@B35-cancers-12-02262],[@B36-cancers-12-02262],[@B37-cancers-12-02262]\]. eIF4G plays a critical role by acting as a multi-faceted scaffold to ensure the assembly of the components required for translation initiation \[[@B38-cancers-12-02262],[@B39-cancers-12-02262]\]. Recent studies have found that eIF4G is related to the occurrence and development of tumors in addition to protein translation. eIF4G is identified as an effective molecular marker and an indicator of tumor progression and prognosis for nasopharyngeal carcinoma \[[@B40-cancers-12-02262]\]. Overexpression of eIF4G promotes the formation of inflammatory breast cancer by reprogramming the protein synthesis to increase the translation of mRNA with the internal ribosomal entry site (IRES) \[[@B41-cancers-12-02262]\]. Furthermore, increased expression of eIF4G is associated with the invasiveness of lung cancer and inflammatory breast cancer \[[@B41-cancers-12-02262],[@B42-cancers-12-02262]\].

Our study illustrates the association between HSP70 and eIF4G in HCC patient tissue samples and demonstrates the effect of HSP70 and eIF4G interaction in protein synthesis, cell proliferation, and apoptosis, suggesting that HSP70--eIF4G interaction may be a potential target for overcoming drug resistance in HCC.

2. Results {#sec2-cancers-12-02262}
==========

2.1. HSP70 and eIF4G Expression Are Significantly Higher in HCC Tumor Specimens {#sec2dot1-cancers-12-02262}
-------------------------------------------------------------------------------

Protein-level of HSP70, eIF4A, eIF4E, eIF4G, and 4EBP1 expression were detected with IF staining in 25 pairs of HCC patient tumor samples and their corresponding adjacent non-tumor tissues. The representative hematoxylin and eosin stain (H&E) and immunofluorescence (IF) staining images and the clinicopathological characteristics of the 25 HCC patients were presented ([Figure 1](#cancers-12-02262-f001){ref-type="fig"}A and [Table 1](#cancers-12-02262-t001){ref-type="table"}). The protein expression of HSP70 and eIF4G was significantly higher in HCC tumor tissues compared to adjacent non-tumor tissues ([Figure 1](#cancers-12-02262-f001){ref-type="fig"}B). To determine whether HSP70 and eIF4G expression are related to the clinicopathological characteristics of HCC patients, we divided 25 patients into two groups based on the protein expression levels of HSP70 and eIF4G. The results of the statistical analysis demonstrated that the expression of HSP70 was significantly related to the Edmondson--Steiner grades (*p* = 0.044, [Table 2](#cancers-12-02262-t002){ref-type="table"}), and the expression of eIF4G correlated with patients' recurrence patterns (*p* = 0.027, [Table 3](#cancers-12-02262-t003){ref-type="table"}). The heatmap depicted the relative protein expression of the HSP70, eIF4A, eIF4E, eIF4G, and 4EBP1 in 25 patients with HCC and the average protein levels of HSP70, eIF4A, eIF4E, eIF4G and 4EBP1 in each TNM stage ([Figure 1](#cancers-12-02262-f001){ref-type="fig"}C,D). We further analyzed the differences in the expression of HSP70 and eIF4G at each TNM stage. The difference between the protein level of HSP70 and eIF4G in each TNM stage did not reach statistical significance ([Figure 1](#cancers-12-02262-f001){ref-type="fig"}E,F). Currently, AFP is considered to be a highly specific indicator for HCC. Elevated AFP levels are closely related to higher pathological grades, more advanced BCLC and TNM stage \[[@B25-cancers-12-02262],[@B43-cancers-12-02262],[@B44-cancers-12-02262],[@B45-cancers-12-02262]\]. The correlation between AFP levels and HSP 70 and eIF4G was further analyzed. However, there was no significant correlation between the AFP level and the protein expression of HSP70 and eIF4G ([Figure 1](#cancers-12-02262-f001){ref-type="fig"}G,H).

2.2. HSP70 and eIF4G Expression is Positively Correlated in Tumor Specimens of Patients with HCC {#sec2dot2-cancers-12-02262}
------------------------------------------------------------------------------------------------

The correlation between HSP70, eIF4A, eIF4E, eIF4G, and 4EBP1 were analyzed with the Pearson correlation coefficient. Compared with the eIF4A, eIF4E, and 4EBP1, HSP70 had the highest correlation with eIF4G in the tumor specimens of HCC patients ([Figure 2](#cancers-12-02262-f002){ref-type="fig"}A,B). Patients with high HSP70 or eIF4G expression showed a trend toward decreased OS and PFS compared to patients with HSP70 or eIF4G low expression, but this did not reach statistical significance ([Figure 2](#cancers-12-02262-f002){ref-type="fig"}C--F). We also assigned patients to the following 4 groups for OS and PFS analysis: low HSP70 expression/low eIF4G expression, high HSP70 expression/low eIF4G expression, low HSP70 expression/high eIF4G expression, and high HSP70 expression/high eIF4G expression. Patients with high HSP70 and eIF4G expression tend to have worse OS and PFS, but this difference was not statistically significant ([Figure 2](#cancers-12-02262-f002){ref-type="fig"}G,H). The correlation between prognostic significance with clinicopathological parameters was studied by univariate and multivariate analysis ([Table 4](#cancers-12-02262-t004){ref-type="table"}). Higher AFP level (≥400 ng/mL), large tumor size (≥5cm), and advanced TNM stage (TNM III) were significantly associated with low PFS (*p* = 0.0368, [Figure 2](#cancers-12-02262-f002){ref-type="fig"}I; *p* = 0.0239, [Figure 2](#cancers-12-02262-f002){ref-type="fig"}J; *p* = 0.0415, [Figure 2](#cancers-12-02262-f002){ref-type="fig"}K). To further understand the effect of HSP70 and eIF4G on prognosis, we used the TCGA dataset to analyze the influence of HSP70 and eIF4G mRNA expression on OS and PFS and found that high HSPA1A or HSPA1B expression is significantly associated with poor OS. A high HSPA1B level was clearly related to poor PFS, while high eIF4G expression was significantly associated with better PFS ([Figure S1A--F](#app1-cancers-12-02262){ref-type="app"}).

2.3. HSP70 Interacts with eIF4G in HCC Cell Lines {#sec2dot3-cancers-12-02262}
-------------------------------------------------

We detected HSP70 expression in sh-eIF4A, sh-eIF4E, sh-eIF4G, and sh-4EBP1 HCC cells. The Western blot results indicated that, compared with sh-eIF4A, sh-eIF4E, and sh-4EBP1, sh-eIF4G had the greatest inhibitory effect on HSP70 expression. In sh-HSP70 cells, eIF4G expression was the most inhibited compared to eIF4A, eIF4E, and 4EBP1 ([Figure 3](#cancers-12-02262-f003){ref-type="fig"}A,B and [Figure S4](#app1-cancers-12-02262){ref-type="app"}). These results demonstrated that the interaction between HSP70 and eIF4G was the most straightforward, in contrast to the interaction between HSP70 and three other genes. We also found that eIF4G expression significantly increased in Flag-HSP70 HepG2 and Huh7 cells, while eIF4G silencing could partially reverse the effect of HSP70 on eIF4G protein expression in cells that overexpressed HSP70 and silenced eIF4G simultaneously ([Figures S2A,B and S4](#app1-cancers-12-02262){ref-type="app"}). We further performed Co-IP assays to verify the interaction between HSP70 and eIF4G in vitro. The cell lysate was immunoprecipitated with Flag antibody, and the eluted fraction was immunoblotted with Flag and eIF4G antibody. The protein band representing the Flag--Hsp70 and eIF4G interaction appeared in Flag--HSP70 HepG2 and Huh7 cells, while no protein band was detected in control cells ([Figure 3](#cancers-12-02262-f003){ref-type="fig"}C and [Figure S4](#app1-cancers-12-02262){ref-type="app"}). Proximity Ligation Assay (PLA) is an experimental method for visualizing endogenous protein interactions \[[@B47-cancers-12-02262]\]. Further in situ PLA assays were carried out to detect the interaction between HSP70 and eIF4G in HCC cell lines and indicated by PLA red signal spots. The number of PLA signals presented in Flag--HSP70 HepG2 and Huh7 cells far exceeded that of the non-transfected cells ([Figure 3](#cancers-12-02262-f003){ref-type="fig"}D). These results indicate that HSP70 interacts with eIF4G in vitro.

2.4. The Interaction between HSP70 and eIF4G Increases under Hypoxia {#sec2dot4-cancers-12-02262}
--------------------------------------------------------------------

Cells were treated with CoCl~2~ to produce a hypoxic environment. The experimental concentration of CoCl~2~ was determined by MTT assays ([Figure 4](#cancers-12-02262-f004){ref-type="fig"}A). The expression of HSP70 and eIF4G in CoCl~2~-treated cells were increased, while sh-HSP70 attenuated the increased expression of eIF4G and sh-eIF4G inhibited the HSP70 expression under hypoxic conditions ([Figure 4](#cancers-12-02262-f004){ref-type="fig"}B,C, [Figures S3A,B and S4](#app1-cancers-12-02262){ref-type="app"}). Co-IP results demonstrated that eIF4G was detected in the CoCl~2~-treated cell lysate precipitated with HSP70 antibody, while little eIF4G expression was detected in the control groups ([Figure 4](#cancers-12-02262-f004){ref-type="fig"}D, [Figures S3C and S4](#app1-cancers-12-02262){ref-type="app"}). Further, the PLA assay showed that the interaction between HSP70 and eIF4G increased under hypoxia ([Figure 4](#cancers-12-02262-f004){ref-type="fig"}E). These results suggest that hypoxia promotes the interaction between HSP70 and eIF4G.

2.5. HSP70--eIF4G Interaction Promotes Cellular Protein Synthesis {#sec2dot5-cancers-12-02262}
-----------------------------------------------------------------

Since the eIF4F complex is so important to initiating protein translation, we investigated the effect of HSP70 and eIF4G interaction on cellular protein translation. The results of our protein synthesis assays indicated that the protein synthesis of HepG2 and Huh7 cells increased when HSP70 was overexpressed and decreased when eIF4G was silenced. Furthermore, eIF4G silencing reversed the effect of HSP70 overexpression on protein synthesis in cells that overexpressed HSP70 and silenced eIF4G simultaneously ([Figure 5](#cancers-12-02262-f005){ref-type="fig"}A,B). Because the eIF4E--eIF4G interaction is a vital step in the initiation of mRNA translation, we detected the influence of HSP70 and eIF4G interaction on eIF4E--eIF4G interaction. PLA assays demonstrated that HSP70 overexpression promoted the eIF4E--eIF4G interaction and eIF4G silencing significantly suppressed this phenomenon, while the role of HSP70 overexpression on eIF4E--eIF4G interaction could be inhibited by eIF4G silencing when cells simultaneously overexpressed HSP70 and silenced eIF4G ([Figure 5](#cancers-12-02262-f005){ref-type="fig"}C,D). These data together demonstrate that the interaction between HSP70 and eIF4G significantly influences cellular protein synthesis.

2.6. HSP70--eIF4G Interaction Promotes Cell Proliferation {#sec2dot6-cancers-12-02262}
---------------------------------------------------------

The regulation of protein translation initiation is the primary mechanism by which cells control protein synthesis. Efficient protein synthesis is essential for cells to perform basic biological functions. Therefore, we investigated whether the HSP70--eIF4G interaction has an impact on cellular proliferation. First, we performed MTT assays to detect cell proliferation and found that the viability of HepG2 and Huh7 cells increased upon HSP70 overexpression and decreased upon eIF4G silencing. In addition, the effect of HSP70 overexpression on cell viabilities could be weakened by eIF4G silencing in cells that overexpressed HSP70 and silenced eIF4G ([Figure 6](#cancers-12-02262-f006){ref-type="fig"}A,B).

Similarly, our colony formation assays showed that HSP70 overexpression contributes to the enhancement of colony unit formation, whereas eIF4G silencing had the opposite effect. The contribution of HSP70 overexpression on colony unit formation could be reversed by eIF4G silencing when cells simultaneously overexpressed HSP70 and silenced eIF4G ([Figure 6](#cancers-12-02262-f006){ref-type="fig"}C,D). These findings demonstrate that HSP70--eIF4G interaction promotes cell proliferation in HepG2 and Huh7 cells.

2.7. HSP70--eIF4G Interaction Inhibits Cell Apoptosis {#sec2dot7-cancers-12-02262}
-----------------------------------------------------

Furthermore, Annexin V-FITC/PI staining apoptosis assays and cell cycle assays were conducted to evaluate the effects of HSP70--eIF4G interaction on cellular apoptosis. Annexin V-FITC/PI staining assays showed that HSP70 overexpression did not affect apoptosis, while eIF4G silencing promoted the proportion of apoptotic HepG2 and Huh7 cells. When cells overexpressed HSP70 and silenced eIF4G simultaneously, the proportion of apoptotic cells also increased compared to the HSP70 overexpressing cells ([Figure 7](#cancers-12-02262-f007){ref-type="fig"}A,B). Similarly, the results of cell cycle assays revealed that the sub-G1 proportion obviously increased in cells overexpressing HSP70 and silencing eIF4G compared with the HSP70 overexpressing cells ([Figure 7](#cancers-12-02262-f007){ref-type="fig"}C,D). Therefore, these results indicate that HSP70--eIF4G interaction inhibits apoptosis in HepG2 and Huh7 cells.

3. Discussion {#sec3-cancers-12-02262}
=============

HSP70 is highly involved in tumor activity at the cellular level and has a strong anti-apoptotic effect. On the one hand, HSP70 prevents the formation of permeability transition pores on the mitochondrial membrane and thereby changes the permeability of the mitochondrial membrane \[[@B17-cancers-12-02262],[@B48-cancers-12-02262]\]. On the other hand, it directly binds to the apoptosis protease activating factor 1 (Apaf-1), which is released by mitochondria and thereby prevents pro-caspase 9 being recruited to the apoptosome \[[@B49-cancers-12-02262]\]. In addition, HSP70 promotes proteasomal degradation of apoptosis signal-regulated kinase 1 (Ask-1) and prevents cell apoptosis by forming a ternary complex with E3 ubiquitin ligase CHIP and Ask-1 \[[@B50-cancers-12-02262]\]. HSP70 also regulates transcription factor NF-κB and HIF-1α activity by interacting with Bag3 to promote tumor progression and metastasis \[[@B51-cancers-12-02262],[@B52-cancers-12-02262]\]. Prior research has shown that HSP70 maintains the stability of HIF-1α by forming a durable complex with HIF-1α under hypoxia \[[@B53-cancers-12-02262],[@B54-cancers-12-02262]\]. HSP70 mediates cisplatin resistance in prostate cancer and is involved in imatinib resistance in chronic myeloid leukemia \[[@B55-cancers-12-02262],[@B56-cancers-12-02262]\]. It was found that HSP70 inhibits the cisplatin-induced apoptosis of the gastric cancer cell line HGC27 by promoting the activation of the mitogen-activated protein kinase (MAPK) signaling pathway \[[@B57-cancers-12-02262]\].

In this study, we firstly identified a significant positive correlation between HSP70 and eIF4G expression in the tumor and adjacent non-tumor tissue of patients with HCC. Evidence suggests that HSP70 or HSC70 may affect the function of specific translation factors, such as Pab1 and eIF4F complex. The HSP70 and Pab1 complex is interpreted as a polysome in yeast, where a deficiency of HSP70 results in a decrease in the Co-IP between HSP70 and Pab1. This finding supports that HSP70 increases translation in yeast by maintaining interaction with Pab1 \[[@B58-cancers-12-02262]\]. Several studies have also posited that HSC70 affects translation initiation through the eIF4F complex. When cells are stressed due to prolonged heat exposure, the increased insolubilization of eIF4G and the decreased association with eIF4E lead to a reduction in the availability of the eIF4F complex. However, this effect is reversed when HSC70 is simultaneously overexpressed \[[@B59-cancers-12-02262]\]. We also demonstrated a direct interaction between HSP70 and eIF4G in vitro that is further enhanced by hypoxic stimulation. eIF4G solubility was maintained by interacting with HSP27, HSC70, and other HSPs, which ensured the eIF4E--eIF4G interaction and preserved only the synthesis of HSPs during prolonged heat stress \[[@B59-cancers-12-02262]\]. The exact mechanism by which heat shock prevents the synthesis of non-heat shock proteins in mammalian cells is not fully understood. We found, however, that the increased interaction between HSP70 and eIF4G protects the eIF4E--eIF4G interaction, which contributes to promoting cellular protein synthesis in HCC cells. Protein production is a prerequisite for cell growth and proliferation. Our results showed that the enhanced interaction between HSP70 and eIF4G promotes cell proliferation in HCC cells. The increased interaction between HSP70 and eIF4G also prevents HCC cells apoptosis. Together, these results demonstrate an obvious and positive correlation between HSP70 and eIF4G in tumor specimens of HCC patients and a direct interaction between HSP70 and eIF4G in HepG2 and Huh7 cells. The enhanced interaction between HSP70 and eIF4G contributes to the increase of cellular protein synthesis and cell proliferation and the inhibition of apoptosis in HCC cells. Interestingly, HSP70 promotes cellular protein synthesis through the interaction with eIF4G under hypoxia, while only the translation of heat shock proteins is protected during heat shock. Why protein translation behaves differently under different stress conditions remains unclear and should be the subject of further study.

A recent phase III trial on the treatment of unresectable HCC showed a 1 year OS of 67.2% after therapy with a combination of the immune checkpoint inhibitor-atezolizumab and the angiogenesis inhibitor--bevacizumab, while 1 year OS was 54.6% after sorafenib treatment \[[@B60-cancers-12-02262]\]. After this new combination therapy was considered by the FDA as a breakthrough in the first-line treatment of advanced or metastatic HCC, it might be a new option towards individualized treatment \[[@B61-cancers-12-02262]\]. Furthermore, a promising OS was achieved after membrane HSP70 (mHSP70) positive stage IIIb non-small cell lung carcinoma (NSCLC) patients were treated with combination therapy of radiochemotherapy (RCT), HSP70 peptide, Interleukin-2 (IL-2) activated NK cells, and PD-1 inhibition \[[@B62-cancers-12-02262]\]. New data discussed the role of HSP70-1A as a new type of angiogenesis regulator that enhanced Interleukin-5 (IL-5) induced angiogenesis in vivo and increased the phosphorylation of the extracellular-signal-regulated kinase (ERK) activating ERK-dependent angiogenesis \[[@B63-cancers-12-02262],[@B64-cancers-12-02262]\]. Therefore, the effect of the combination of immune checkpoint inhibitors and angiogenesis inhibitors on the interaction of HSP70 and eIF4G needs to be explored further.

4. Materials and Methods {#sec4-cancers-12-02262}
========================

4.1. Clinical Specimens {#sec4dot1-cancers-12-02262}
-----------------------

Twenty-five pairs of liver tumor and adjacent non-tumor tissues excluding tumor margins were obtained from randomly selected pseudonymized HCC patients who underwent liver resection. Tissue was collected after patients gave their informed consent and the study was approved by the Ethics Committee of the Medical Faculty of the University of Heidelberg (ethic vote: S-557/2017). Clinical characteristics are provided in [Table 1](#cancers-12-02262-t001){ref-type="table"}.

4.2. Cell Culture and Reagents {#sec4dot2-cancers-12-02262}
------------------------------

The human HCC cell lines HepG2 (Toni 10 Lindl GmbH, Munich, Germany) and Huh7 (European Cell Culture Collection) were incubated in Dulbecco's Modified Eagle's medium (Sigma-Aldrich, Munich, Germany) supplemented with 10% fetal bovine serum (Biochrom GmbH, Darmstadt, Germany), 100 U/mL penicillin, and 0.1 mg/mL streptomycin (Sigma-Aldrich, Munich, Germany). The cells were cultured in a 37 °C humidified incubator with a 5% CO~2~ atmosphere. A stock solution of Cobalt chloride (CoCl~2~; Sigma-Aldrich, Munich, Germany) with a concentration of 10 mM was prepared using phosphate-buffered saline (PBS).

4.3. Immunofluorescence (IF) {#sec4dot3-cancers-12-02262}
----------------------------

Tissue sections stored at −20 °C were rinsed in cold TBST for 2 × 5 min and then rinsed in cold PBS for 5 min. Slides were blocked with 100 μL of 10% pure goat serum and incubated for 1 h at room temperature. After being washed with TBST, the slides were incubated overnight with 50 μL of primary antibodies diluted solution (1:100) at 4 °C. Fluorescent-conjugated secondary antibodies (Cy2 and Cy3) were diluted to a concentration of 1:400 with DAKO Antibody Diluent (Agilent Technologies, Santa Clara, CA, USA). An amount of 50 μL of the secondary antibody diluent was added to each reaction area and the samples were cultured at room temperature for 1 h. Finally, each reaction area was incubated with 4′,6-diamidino-2-phenylindole (DAPI, 1:1000, Sigma-Aldrich, Munich, Germany) for 10 min at room temperature and fixed with Dako Mounting Medium (Agilent Technologies, Santa Clara, CA, USA). Negative controls were incubated with replacement of the primary antibody with DAKO Antibody Diluent. Detection was performed by microscope and analyzed with the free software ImageJ (<http://imagej.nih.gov/ij/>). Patients with higher average fluorescence intensity of HSP70 or eIF4G expression in tumor samples than that in adjacent non-tumor tissues are defined as "high HSP70 or eIF4G expression", on the contrary, they're defined as "low HSP70 or eIF4G expression". The primary antibodies HSP70 (4873S), eIF4E (2067S), eIF4G (2498S), and 4E-BP1 (9644S) were purchased from Cell Signaling Technology (Danvers, MA, USA). eIF4A (sc-377315) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

4.4. Gene Survival Analysis {#sec4dot4-cancers-12-02262}
---------------------------

The OS and PFS curves of HSPA1A, HSPA1B, and eIF4G were obtained online, from Kaplan Meier Plotter (<http://kmplot.com/analysis/>) and based on The Cancer Genome Atlas (TCGA) (<http://cancergenome.nih.gov>) \[[@B65-cancers-12-02262]\]**.**

4.5. Short Hairpin RNA (shRNA), Small Interfering RNA (siRNA), and Flag-HSP70 Plasmid Transfection {#sec4dot5-cancers-12-02262}
--------------------------------------------------------------------------------------------------

Cells were seeded at a density of 1.5 × 10^5^--2.5 × 10^5^ in 6-well plates and incubated overnight in normal growth medium without antibiotics. eIF4A shRNA Plasmid (h) (SC-40554-SH), eIF4G shRNA Plasmid (h) (SC-40558-SH), eIF4E shRNA Plasmid (h) (SC-35284-SH), 4EBP shRNA Plasmid (h) (SC-29594-SH), HSP70 shRNA Plasmid (h) (SC-29352-SH), and eIF4G siRNA (h) (sc-35286) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). pCMV3-N-FLAG-HSP70 plasmid (HG11660-NF) was obtained from Sino Biological (Eschborn, Germany). Transfection was performed according to the manufacturer's protocol. Forty-eight hours post-transfection, shRNA transfected cells were incubated for 14 days in fresh medium containing 1 μg/mL puromycin to determine which cells stably expressed HSP70. The resulting findings were then confirmed by Western blot. Seventy-two hours after transfection with the pCMV3-N-FLAG-HSP70 plasmid, stably transfected cells were selected with hygromycin and identified by Western blot.

4.6. Co-Immunoprecipitation (Co-IP) {#sec4dot6-cancers-12-02262}
-----------------------------------

Transfection and CoCl~2~ treatment were performed with the Pierce™ Co-Immunoprecipitation Kit (Thermo Scientific, Waltham, MA, USA) according to the manufacturer's protocol. Cell lysates were immunoprecipitated with anti-Flag Tag monoclonal antibody or HSP70 antibody. The presence of HSP70 and eIF4G in the eluted fractions from the cross-linked resin was analyzed via Western blot.

4.7. Cell Proliferation Assay {#sec4dot7-cancers-12-02262}
-----------------------------

Cells/well measuring 5 × 10^3^ were seeded in a 96-well plate and treated with 25, 50, 10, 200, 400, 800, and 1600 µM CoCl~2~ for 24, 48, and 72 h, respectively. Cell viability was measured to calculate the 50% cell growth inhibitory concentrations (IC50) value of CoCl~2.~ Cells were seeded in 96-well plates with 1 × 10^3^ cells/well and treated with 10 μM CoCl~2~. Cell absorbancy at a wavelength of 570 nm (with a reference wavelength of 630 m) was measured daily for 6 days after treatment, to evaluate cell proliferation.

4.8. Western Blot {#sec4dot8-cancers-12-02262}
-----------------

Cells were seeded in 6-well plates at a density of 1 × 10^6^ cells/well. After treatment with 10 μM CoCl~2~ for 12 h, cells were lysed and the concentration of each sample was detected with the Pierce^®^ BCA Protein Assay Kit (Thermo Scientific, Waltham, MA, USA). A 4--12% Bis-Tris SDS-PAGE gel (Thermo Scientific, Waltham, MA, USA) was used to run protein samples at 200 V for 50 min. Proteins were transferred to a nitrocellulose membrane and run for 1.5 h at 40 V. All primary antibodies were diluted to a concentration of 1:1000 using a blocking solution and then incubated overnight at 4 °C. The membrane was then blocked with 5% BSA for 1 h at room temperature and cultured with the IRDye^®^ 680RD Goat anti-Mouse/Rabbit IgG secondary antibody (1:10,000, LI-COR Biosciences, Lincoln, Nebraska, USA) at room temperature for 1 h. Next, the membranes were visualized using an Odyssey CLx scanner (LI-COR Bioscience, Lincoln, Nebraska, USA) and the scanner results obtained using Image Studio software (LI-COR Bioscience, Lincoln, Nebraska, USA). The primary antibodies HIF-1a (79233S), p-eIF4E (9741A), p-4EBP1 (2855S), and β-actin (3700S) were obtained from Cell Signaling Technology (Danvers, MA, USA).

4.9. Colony Formation Assay {#sec4dot9-cancers-12-02262}
---------------------------

Cells were plated in 6-well plates with a density of 400 cells/well. After treatment with 10 μM CoCl~2~, cells were incubated at 37 °C for 14 days. Cells were fixed with 4% paraformaldehyde (PFA) solution and stained with 0.05% Coomassie-blue for 5 min. Cells were analyzed with a binocular microscope and the colonies counted with the help of a counting-grid. Plating efficiency (PE) was calculated by the following formula: PE (%) = 100 × number of counted colonies/number of cells seeded.

4.10. Annexin V-FITC/PI Staining Apoptosis Assay and Cell Cycle Assay {#sec4dot10-cancers-12-02262}
---------------------------------------------------------------------

Cells (1 × 10^6^/well) were placed in 6-well plates and treated with 10 μM CoCl~2~ for 48 h before being collected and re-suspended in 500µL of 1 x Binding Buffer. After, 5µL of Annexin V-FITC and 5 µL of propidium iodide (PI) were added to each sample. Cells were then incubated in a dark room at room temperature for 15 min. Annexin V-FITC/PI binding was detected by Fluorescence-activated cell sorting (FACS; CellQuest analysis program, BD Biosciences, Heidelberg, Germany) and analyzed with Flowjo software ([www.flowjo.com](www.flowjo.com)). The Annexin V-FITC Apoptosis Kit from Bioversion was used (Buckingham, UK). For cell cycle assays, cells were harvested and stained with PI; cell cycle distribution was analyzed via flow cytometry.

4.11. Click-iT^®^ HPG Alexa Fluor^®^ Protein Synthesis Assay {#sec4dot11-cancers-12-02262}
------------------------------------------------------------

Cells (4 × 10^4^ cells/well) were plated into 8-well culture slides and treated with 10 μM CoCl~2~ for 12 h and the following steps were performed based on the manufacturer's protocol of the Click-iT^®^ HPG Alexa Fluor^®^ Protein Synthesis Assay Kit (Thermo Scientific, Waltham, MA, USA). The signal of samples was detected using a fluorescence microscope (Leica Leitz DMRB, Wetzlar, Germany) and counted through semi-automated image analysis using ImageJ Software.

4.12. In Situ Proximity Ligation Assay {#sec4dot12-cancers-12-02262}
--------------------------------------

Cells (4 × 10^4^ cells/well) were plated into 8-well culture slides and treated with 10 μM CoCl~2~ for 12 h. The following steps were carried out according to the Duolink^®^ PLA Protocol (Sigma-Aldrich, Munich, Germany). The number of PLA signals was detected with a fluorescence microscope (Leica Leitz DMRB, Wetzlar, Germany) and a high-resolution Spot Flex camera (Visitron Systems, Puchheim, Germany). Afterwards, the red blobs were counted through semi-automated image analysis with free BolbFinder v3.2 Software (Uppsala University, Sweden). Duolink^®^ In Situ Detection Reagents Red, Duolink^®^ In Situ PLA^®^ Probe Anti-Mouse MINUS and Anti-Rabbit PLUS were obtained from Sigma-Aldrich (Munich, Germany). HSP70 Mouse mAb (46477S) and eIF4E Mouse mAb (2067S) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

4.13. Statistical Analysis {#sec4dot13-cancers-12-02262}
--------------------------

All statistical calculations were performed using GraphPad Prism 7 software. Unpaired Student's t-test was used to analyze differences between two groups and one-way ANOVA was used to analyze differences among multiple groups. Fisher's exact test was carried out for comparing qualitative variables. Pearson correlation analysis was used to examine relationships between different gene expressions. OS and PFS were calculated from the date of surgery to recurrence, death, or last follow-up. The Kaplan--Meier method was used to analyze the OS and PFS curves. Univariate and multivariate analysis of OS and PFS according to clinicopathological characteristics was performed using the log-rank test. Data are shown as mean ± SD. *p* \< 0.05 was considered statistically significant.

5. Conclusions {#sec5-cancers-12-02262}
==============

The present study reveals a strong positive correlation between HSP70 and eIF4G in HCC patient tumor specimens and a direct interaction between HSP70 and eIF4G in vitro. HSP70 maintains protein synthesis by interacting with eIF4G, thereby promoting cell proliferation and inhibiting apoptosis in HCC cells. Therefore, targeting HSP70 and eIF4G interactions may be an effective mode of future HCC therapy.
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![HSP70 and eIF4G expression are significantly higher in hepatocellular carcinoma (HCC) tumor specimens. (**A**) Representative pictures of H&E and IF staining. Magnification, 20×; Scale bar, 50μm. (**B**) The protein levels of HSP70 and eIF4G in HCC tumor specimens were significantly higher than those of adjacent non-tumor specimens. (**C**) Heatmap showing the relative protein expression of eIF4A, eIF4E, eIF4G, 4EBP1, and HSP70 in all HCC patients tissue samples based on IF staining results. (**D**) Heatmap showing the average relative protein expression of eIF4A, eIF4E, eIF4G, 4EBP1, and HSP70 in all patients in each TNM stage. (**E**,**F**) Protein expression of HSP70 and eIF4G in HCC patients displayed according to the TNM stage. (**G**,**H**) The scatter plot of correlation between the AFP level and the protein expression of HSP70 and eIF4G. \* *p* \< 0.05, \*\*\* *p* \< 0.001 compared with the adjacent non-tumor groups.](cancers-12-02262-g001){#cancers-12-02262-f001}

![The expression of HSP70 and eIF4G positively correlated in tumor specimens of patients with HCC. High and low expression of HSP70 or eIF4G are defined in Materials and Methods. (**A**) Correlation plot showing the relationships between HSP70 and eIF4A, eIF4E, eIF4G, and 4EBP1, respectively. Light blue indicates the highest correlation while light red indicates the lowest correlation. (**B**) The relative protein expression of HSP70 and eIF4G in HCC tissues was positively correlated. (**C**,**D**) The OS and PFS in HCC patients with high and low HSP70 expression were evaluated. (**E**,**F**) The OS and PFS of HCC patients were assessed based on high and low eIF4G expression. (**G**,**H**) HCC patients were divided into four groups of low HSP70 expression/low eIF4G expression, high HSP70 expression/low eIF4G expression, low HSP70 expression/high eIF4G expression, and high HSP70 expression/high eIF4G expression. The OS and PFS of each group were analyzed. (**I**--**K**) The PFS of HCC patients was compared according to clinical features of AFP level (**I**), tumor size (**J**), and TNM stage (**K**). The survival curves were plotted by the Kaplan-Meier method, and *p* values were calculated by the log-rank test.](cancers-12-02262-g002){#cancers-12-02262-f002}

![HSP70 interacts with eIF4G in vitro. (**A**,**B**) Cell lysates were analyzed with a Western blot to detect the protein level by using primary antibodies targeting eIF4A, eIF4E, eIF4G, 4EBP1, and HSP70. β-actin was used as an internal control. (**C**) Flag-HSP70 immunoprecipitated eIF4G from the cell lysates of HepG2 and Huh7 cells transfected with or without Flag-HSP70 plasmid. Immunoprecipitates were analyzed with Flag or eIF4G antibodies via Western blot. (**D**) The HSP70-eIF4G interaction was detected by in situ PLA. Flag-HSP70 transfected cells and control cells were incubated with mouse anti-HSP70 mAb and rabbit anti-eIF4G mAb. Red signal spots are shown to indicate the protein interaction between HSP70 and eIF4G. Magnification 20×; Scale bar 50 μm. Quantitative data from three experiments with similar results were analyzed. Data are presented as mean ± standard deviation (SD). \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001 compared with corresponding control groups.](cancers-12-02262-g003){#cancers-12-02262-f003}

![The HSP70 and eIF4G interaction increases under hypoxia. (**A**) HepG2 and Huh7 cells were treated as described in the methods section. IC50 of CoCl2 in HepG2 and Huh7 cells were calculated based on cell viability assessed by MTT assay, and the results presented as a ratio with the control group. (**B**,**C**) Cells were treated with 10 µM CoCl~2~ for 12 h and the protein levels of the eIF4F complex and HSP70 detected by Western blot. β-actin was used as an internal control. (**D**) Cells were incubated with 10 µM CoCl2 for 12 h and the protein of eIF4G immunoprecipitated from the cell lysates of HepG2 and Huh7 cells with HSP70 antibody. The immunoprecipitates were analyzed via Western blot with HSP70 and eIF4G antibodies. (**E**) Cells were stimulated with 10 µM CoCl~2~ for 12 h and the HSP70--eIF4G interaction in situ was detected by PLA assay. Representative images are shown. Magnification 20×; Scale bar 50 μm. Quantitative data from three experiments with similar results were analyzed. Data are presented as mean ± SD. \*\* *p* \< 0.01 compared with corresponding control groups.](cancers-12-02262-g004){#cancers-12-02262-f004}

![HSP70--eIF4G interaction promotes cellular protein synthesis. (**A**,**B**) Cells were incubated with 10 µM CoCl~2~ for 12 h; each group was then examined via protein synthesis assay. Representative pictures of protein synthesis are shown. Magnification 20×; Scale bar 50 μm. (**C**,**D**) Cells were cultivated with 10 µM CoCl~2~ for 12 h and the eIF4G-eIF4E interaction examined in situ for each group. Representative images of the PLA assay are presented. Magnification 20×; Scale bar 50 μm. Quantitative data from three experiments with similar results were analyzed. Data are presented as mean ± SD. \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001, \*\*\*\* *p* \< 0.0001 compared with corresponding control groups.](cancers-12-02262-g005){#cancers-12-02262-f005}

![HSP70--eIF4G interaction promotes cell proliferation. (**A**,**B**) Cells were incubated with 10 μM CoCl~2~ for 5 days; cell viability was measured daily. (**C**,**D**) Cells treated with 10 μM CoCl~2~; colony units were counted after 14 days of incubation. Quantitative data from three experiments with similar results were summarized. Data are presented as mean ± SD. ns: not significant, \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\*\* *p* \< 0.0001 compared with corresponding control groups.](cancers-12-02262-g006){#cancers-12-02262-f006}

![HSP70--eIF4G interaction inhibits cell apoptosis. (**A**,**B**) Cells were incubated with 10 μM CoCl~2~ for 48 h. Annexin-V and PI were used to stain the treated cells and flow cytometry analysis was performed to assess the rate of cell apoptosis. (**C**,**D**) Cells treated with 10 μM CoCl~2~ for 48 h. The percentage of the Sub-G1 portion of the cell cycle distribution was quantified by flow cytometry analyses after PI staining. Quantitative data from three experiments with similar results were summarized. Data presented as mean ± SD. ns: not significant, \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001, \*\*\*\* *p* \< 0.0001 compared to corresponding control groups.](cancers-12-02262-g007){#cancers-12-02262-f007}

cancers-12-02262-t001_Table 1

###### 

Clinicopathological Characteristics of HCC Patients.

  Characteristic            Group                   *N* = 25   Ratio (% of Total N)   *p* Value
  ------------------------- ----------------------- ---------- ---------------------- ---------------
  Gender                    Male                    16         64%                    
                            Female                  9          36%                    
  Age (years)               \<50                    3          12%                    
                            ≥50                     22         88%                    
  AFP (ng/mL)               \<400                   17         68%                    
                            ≥400                    8          32%                    
  Etiology                  Hepatitis B             2          8%                     
                            Hepatitis C             7          28%                    
                            Alcohol                 6          24%                    
                            NASH                    2          8%                     
                            Autoimmune              1          4%                     
                            Vinyl chloride          1          4%                     
                            Colorectal metastasis   1          4%                     
                            Unknown                 5          20%                    
  Liver cirrhosis           Present                 12         48%                    
                            Absent                  13         52%                    
  Tumor size (cm)           \<5                     17         68%                    
                            ≥5                      8          32%                    
  Tumor number              Single                  19         76%                    
                            Multiple                6          24%                    
  Edmondson-Steiner grade   G1                      1          4%                     
                            G2                      14         56%                    
                            G3                      10         40%                    
  ECGO PS                   0                       23         92%                    
                            1                       2          8%                     
  Child-Pugh class          A                       24         96%                    
                            B                       1          4%                     
  BCLC stage                0 + A                   20         80%                    
                            B                       5          20%                    
  TNM stage                 I + II                  16         64%                    
                            III                     9          36%                    
  Recurrence                Positive                12         48%                    
                            Negative                13         52%                    
  Recurrence Pattern        Intrahepatic only       9          75%                    
  *n* = 12                  Extrahepatic only       1          8.33%                  
                            Both                    2          16.67%                 
  Ki-67 expression          High                    11         44%                    
                            Low                     14         56%                    
  Midkine expression        High                    15         60%                    
                            Low                     10         40%                    
  HSP70 high expression     Tumor tissue            18         72%                    0.0042 \*\*
                            Non-Tumor tissue        7          30%                    
  eIF4A high expression     Tumor tissue            12         48%                    \>0.9999
                            Non-Tumor tissue        13         52%                    
  eIF4E high expression     Tumor tissue            14         56%                    0.5721
                            Non-Tumor tissue        11         44%                    
  eIF4G high expression     Tumor tissue            19         76%                    0.0005 \*\*\*
                            Non-Tumor tissue        6          24%                    
  4EBP1 high expression     Tumor tissue            10         40%                    0.2578
                            Non-Tumor tissue        15         60%                    
  Stage                     T                       N          M                      
  I                         T1                      N0         M0                     
  II                        T2                      N0         M0                     
  IIIa                      T3a                     N0         M0                     
  IIIb                      T3b                     N0         M0                     
  IIIc                      T4                      N0         M0                     
  IVa                       Any T                   N1         M0                     
  IVb                       Any T                   Any N      M1                     

Patient staging is based on the BCLC stage and TNM stage as described in the seventh edition of the UICC-AJCC Cancer Staging Manual \[[@B46-cancers-12-02262]\]. Abbreviations: AFP, alpha-fetoprotein; NASH, nonal- coholic steatohepatitis; ECGO PS, Eastern Cooperative Oncology Group Performance Status; BCLC, Barcelona clinic liver cancer; TNM, Tumor, Node, Metastasis; \*\*, *p* \< 0.01; \*\*\*, *p* \< 0.001.

cancers-12-02262-t002_Table 2

###### 

Correlation between HSP70 Expression and Clinicopathological Characteristics in HCC Patients.

  Characteristic            Group                   HSP70 High Expression   HSP70 Low Expression   *p* Value
  ------------------------- ----------------------- ----------------------- ---------------------- -----------
  Gender                    Male                    9                       7                      0.4013
                            Female                  7                       2                      
  Age (years)               \<50                    3                       0                      0.5343
                            ≥50                     15                      7                      
  AFP (ng/mL)               \<400                   12                      5                      \>0.9999
                            ≥400                    6                       2                      
  Etiology                  Hepatitis B             2                       0                      0.7124
                            Hepatitis C             4                       3                      
                            Alcohol                 5                       1                      
                            NASH                    1                       1                      
                            Autoimmune              1                       0                      
                            Vinyl chloride          0                       1                      
                            Colorectal metastasis   0                       1                      
                            Unknown                 5                       0                      
  Liver cirrhosis           Present                 9                       3                      \>0.9999
                            Absent                  9                       4                      
  Tumor size (cm)           \<5                     11                      6                      0.3623
                            ≥5                      7                       1                      
  Tumor number              Single                  15                      4                      0.2985
                            Multiple                3                       3                      
  Edmondson-Steiner grade   G1                      0                       1                      0.0439 \*
                            G2                      9                       5                      
                            G3                      9                       1                      
  ECGO PS                   0                       16                      7                      \>0.9999
                            1                       2                       0                      
  Child-Pugh class          A                       17                      7                      \>0.9999
                            B                       1                       0                      
  BCLC stage                0 + A                   16                      4                      0.1130
                            B                       2                       3                      
  TNM stage                 I + II                  10                      6                      \>0.9999
                            III                     6                       3                      
  Recurrence                Positive                10                      2                      0.3783
                            Negative                8                       5                      
  Recurrence Pattern        Intrahepatic only       8                       1                      0.5665
  *N* = 12                  Extrahepatic only       1                       0                      
                            Both                    2                       0                      
  Ki-67 expression          High                    7                       4                      0.6564
                            Low                     11                      3                      
  Midkine expression        High                    10                      5                      0.6592
                            Low                     8                       2                      
  Patient survival (%)      1-year OS               82.35                   83.33                  0.7055
                            1-year PFS              47.06                   62.5                   0.1031
                            3-year OS               49.91                   83.33                  0.5712
                            3-year PFS              37.65                   62.5                   0.5290
                            5-year OS               49.91                   0                      0.5528
                            5-year PFS              37.65                   0                      0.3706

Abbreviations: \*, *p* \< 0.05; PFS, progression-free survival.

cancers-12-02262-t003_Table 3

###### 

Correlation between eIF4G Expression and Clinicopathological Characteristics in HCC Patients.

  Characteristic            Group                   eIF4G High Expression   eIF4G Low Expression   *p* Value
  ------------------------- ----------------------- ----------------------- ---------------------- -----------
  Gender                    Male                    13                      3                      0.6300
                            Female                  6                       3                      
  Age (years)               \<50                    1                       2                      0.1326
                            ≥50                     18                      4                      
  AFP (ng/mL)               \<400                   11                      6                      0.1292
                            ≥400                    8                       0                      
  Etiology                  Hepatitis B             1                       1                      0.0812
                            Hepatitis C             7                       0                      
                            Alcohol                 6                       0                      
                            NASH                    1                       1                      
                            Autoimmune              0                       1                      
                            Vinyl chloride          1                       0                      
                            Colorectal metastasis   0                       1                      
                            Unknown                 3                       2                      
  Liver cirrhosis           Present                 10                      2                      0.6447
                            Absent                  9                       4                      
  Tumor size (cm)           \<5                     13                      4                      \>0.9999
                            ≥5                      6                       2                      
  Tumor number              Single                  13                      6                      0.2778
                            Multiple                6                       0                      
  Edmondson-Steiner grade   G1                      0                       1                      0.0694
                            G2                      10                      4                      
                            G3                      9                       1                      
  ECGO PS                   0                       18                      5                      0.4300
                            1                       1                       1                      
  Child-Pugh class          A                       19                      5                      0.2400
                            B                       0                       1                      
  BCLC stage                0 + A                   15                      5                      \>0.9999
                            B                       4                       1                      
  TNM stage                 I + II                  11                      5                      0.3644
                            III                     8                       1                      
  Recurrence                Positive                10                      2                      0.6447
                            Negative                9                       4                      
  Recurrence Pattern        Intrahepatic only       9                       0                      0.0271 \*
  *n* = 12                  Extrahepatic only       0                       1                      
                            Both                    1                       1                      
  Ki-67 expression          High                    9                       2                      0.6609
                            Low                     10                      4                      
  Midkine expression        High                    12                      3                      0.6532
                            Low                     7                       3                      
  Patient survival (%)      1-year OS               75.89                   100                    \>0.9999
                            1-year PFS              41.32                   80                     0.0953
                            3-year OS               38.55                   100                    0.1861
                            3-year PFS              27.55                   80                     0.2774
                            5-year OS               0                       100                    0.1753
                            5-year PFS              0                       80                     0.2335

Abbreviations: \*, *p* \< 0.05.

cancers-12-02262-t004_Table 4

###### 

Association between Clinicopathological Characteristics and Prognosis in HCC Patients.

  Characteristic                OS     PFS              
  ----------------------------- ------ -------- ------- -----------
  **Gender**                                            
  Male                          5/16   0.6030   7/16    0.9294
  Female                        4/9             6/9     
  **Age (years)**                                       
  \<50                          1/3    0.4527   1/3     0.2139
  ≥50                           8/22            12/22   
  **AFP (ng/mL)**                                       
  \<400                         5/17   0.1863   7/17    0.0368 \*
  ≥400                          4/8             6/8     
  **Etiology**                                          
  Hepatitis B                   0/2    0.2367   0/2     0.3502
  Hepatitis C                   2/7             3/7     
  Alcohol                       2/6             3/6     
  NASH                          1/2             1/2     
  Autoimmune                    0/1             0/1     
  Vinyl chloride                0/1             1/1     
  Colorectal metastasis         0/1             0/1     
  Unknown                       4/5             5/5     
  **Liver cirrhosis**                                   
  Present                       4/12   0.6010   5/12    0.2579
  Absent                        5/13            8/13    
  **Tumor size (cm)**                                   
  \<5                           5/17   0.4959   6/17    0.0239 \*
  ≥5                            4/8             7/8     
  **Tumor number**                                      
  Single                        6/19   0.0744   9/19    0.1204
  Multiple                      3/6             4/6     
  **Edmondson-Steiner grade**                           
  G1                            0/1    0.5090   0/1     0.9778
  G2                            4/14            7/14    
  G3                            5/10            6/10    
  **ECGO PS**                                           
  0                             8/23   0.7663   12/23   0.4295
  1                             1/2             1/2     
  **Child-Pugh class**                                  
  A                             9/24   0.4214   13/24   0.3483
  B                             0/1             0/1     
  **BCLC stage**                                        
  0 + A                         8/20   0.4364   10/20   0.6930
  B                             1/5             3/5     
  **TNM stage**                                         
  I + II                        4/16   0.4385   5/16    0.0415 \*
  III                           5/9             8/9     
  **Recurrence**                                        
  Positive                      5/12   0.7374   9/12    0.3079
  Negative                      4/13            4/13    
  **Recurrence Pattern**                                
  Intrahepatic only             4/9    0.6937   6/9     0.3380
  Extrahepatic only             1/1             1/1     
  Both                          0/2             2/2     
  **Ki-67 expression**                                  
  High                          3/11   0.2863   5/11    0.6943
  Low                           6/14            8/14    
  **Midkine expression**                                
  High                          4/15   0.5037   6/15    0.4995
  Low                           5/10            7/10    

Abbreviations: \*, *p* \< 0.05.

[^1]: These authors have contributed equally to this work.
